Incidence and risk of heart failure in systemic lupus erythematosus

Kim, Chang H.; Al‐Kindi, Sadeer G.; Jandali, Bochra; Askari, Alireza; Zacharias, M.; Oliveira, Guilherme H.

doi:10.1136/heartjnl-2016-309561

Cited by 86 publications

(66 citation statements)

References 29 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The platform has been applied to validation and epidemiologic studies across other disciplines. 15,16 In this analysis, all active nondeceased patients in the database at the time of our query (October 1, 2016) were included in this study. The SNOMED-CT term hidradenitis has one-to-one mapping to the ICD-9 code for HS (705.83) and was used to identify patients with the ICD-9 code.…”

mentioning

confidence: 99%

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

et al. 2017

View full text Add to dashboard Cite

idradenitis suppurativa (HS) is a debilitating, painful chronic inflammatory disease for which the inherent unpredictability with respect to the course of disease and response to treatment poses significant challenges for patients. With sparse epidemiologic data for HS, disease burden has not yet been established. The prevalence of HS has been estimated using claims analyses, examinations, medical record reviews, or patient-administered questionnaires. Most prevalence studies have involved selected samples and/or small cohorts, which limit generalizability. Because of the different data acquisition methods, study settings, and geographic samples in these analyses, prevalence estimates have, not surprisingly, varied significantly across the world. Overall prevalence estimates for HS in Europe and in the United States have ranged from 0.00033% to as high as 4.1%. 1-10 Few adjusted population analyses on which HS prevalence may be accurately estimated have been performed. The true overall prevalence of HS is therefore unknown. The purpose of our study was to establish standardized prevalence estimates for HS in the overall US population and in specific demographic subgroups. Methods Case IdentificationWe performed a retrospective case cohort analysis by querying a multi-institutional data analytics and research platform (Explorys) developed by IBM Watson Health. 11 Clinical information from electronic medical records, laboratories, practice management systems, and claims systems is matched using the single set of Unified Medical Language System ontologies IMPORTANCE The true prevalence of hidradenitis suppurativa (HS) is unknown. OBJECTIVE To establish standardized overall and group-specific prevalence estimates for HS in the United States. DESIGN, SETTING, AND PARTICIPANTSThis retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. As of October 27, 2016, a total of 47 690 patients with HS were identified using electronic health record data. MAIN OUTCOMES AND MEASURESStandardized overall point prevalence for HS and sex-, age-, and race-specific prevalence estimates of HS in the general US population. RESULTSOf the 47 690 patients with HS (26.2% men and 73.8% women), the overall HS prevalence in the US population sample was 0.10%, or 98 per 100 000 persons (95% CI, 97-99 per 100 000 persons). The adjusted prevalence in women was 137 per 100 000 (95% CI, 136-139 per 100 000), more than twice that of men (58 per 100 000; 95% CI, 57-59 per 100 000; P < .001). The prevalence of HS was highest among patients aged 30 to 39 years (172 per 100 000; 95% CI, 169-275 per 100 000) compared with all other age groups (range, 15-150 per 100 000; P < .001). Adjusted HS prevalences among African American (296 per 100 000; 95% CI, 291-300 per 100 000) and biracial (218 per 100 000; 95% CI, 202-235 per 100 000) patients were more than 3-fold and 2-fold greater, respectively, than that among white patients (95 per 100 000; 95% CI, 94-9...

show abstract

mentioning

confidence: 99%

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Adicionalmente, las anomalías valvulares cardiacas son hallazgos frecuentes en los pacientes con LES y pueden estar asociadas a la presencia de anticuerpos antifosfolipídicos. Aunque la mortalidad total de pacientes con LES ha mejorado en las últimas tres décadas con los avances en el tratamiento y una mejor comprensión de los mecanismos patológicos, la mortalidad debido a la enfermedad cardiovascular permanece igual [21,22]. Los mecanismos subyacentes a una acelerada aterosclerosis en el LES son complejos y son áreas de activa investigación.…”

Section: Discussionunclassified

Cardiovascular events in patients with systemic lupus erythematosus and their association with cardiovascular risk factors

Acosta-Colmán

Ávila-Pedretti

Aquino-Valdovinos

et al. 2017

Mem. Inst. Investig. Cienc. Salud

View full text Add to dashboard Cite

“…У пациентов с СКВ частота собственно КВЗ (ИБС, ИМ, инсульт, поражение периферических сосудов) и ТФР (АГ, СД, дислипидемия, ожирение) выше, чем в общей по-пуляции [4][5][6][7][8][9][10][11][12]. Кроме высокого риска ИБС и АГ, у паци-ентов с СКВ чаще встречаются состояния, потенциально опасные в отношении развития СН: анемия, хроническая болезнь почек (ХБП), заболевания щитовидной железы, поражения клапанов, нарушения ритма и проводимости сердца, легочная гипертензия [12].…”

unclassified

“…Кроме высокого риска ИБС и АГ, у паци-ентов с СКВ чаще встречаются состояния, потенциально опасные в отношении развития СН: анемия, хроническая болезнь почек (ХБП), заболевания щитовидной железы, поражения клапанов, нарушения ритма и проводимости сердца, легочная гипертензия [12]. Логично предполо-жить, что частота самой СН в этой группе больных долж-на быть выше.…”

unclassified

“…было опуб-ликовано первое масштабное исследование, посвященное частоте и факторам риска СН у пациентов с СКВ [12]. Это ретроспективное наблюдение, включающее более 45 млн человек, обследованных в клиниках США с 1999 г. по ап-рель 2016 г. по разным причинам.…”

unclassified

See 1 more Smart Citation

Heart Failure in Systemic Lupus Erythematosus: Risk Factors and Diagnostic Features

Panafidina¹,

Popkova²

2018

rsp

View full text Add to dashboard Cite

With increased survival in patients with systemic lupus erythematosus (SLE), cardiovascular diseases have become the main causes of death. Heart failure (HF) is the final stage of the cardiovascular continuum; decompensation of this condition commonly results in death. Studies of HF, its frequency, risk factors, and diagnostic features in patients with SLE are extremely few. The paper details data on the definition, frequency, current classification, and the algorithm for the diagnosis of HF and comparatively analyzes the risk factors of the latter in the general population and among patients with SLE. HF diagnostic problems in this patient category and possible ways of their resolution are discussed.

show abstract

Incidence and risk of heart failure in systemic lupus erythematosus

Abstract: The findings of this study suggest that patients with SLE have significantly higher risk of developing HF and a worse cardiovascular risk profile compared with the general population. These results need to be confirmed by prospective studies.

Cited by 86 publications

References 29 publications

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

Cardiovascular events in patients with systemic lupus erythematosus and their association with cardiovascular risk factors

Heart Failure in Systemic Lupus Erythematosus: Risk Factors and Diagnostic Features

Contact Info

Product

Resources

About